罗格列酮对2型糖尿病病人肿瘤坏死因子和瘦素的影响

Effects of rosiglitazone on tumor necrosis factor and leptin in type 2 diabetic patients

目的 :探讨罗格列酮治疗 2型糖尿病对肿瘤坏死因子 (TNF)和瘦素的影响及其治疗糖尿病的可能机制。方法 :4 8例 2型糖尿病病人 ,男性 2 4例 ,女性 2 4例 ,年龄 (5 8±s 8)a ,随机分为 2组 ,每组 2 4例 ,对照组维持原磺酰脲类和双胍类药物降糖治疗 ,治疗组在原治疗基础上加用罗格列酮 4mg·d- 1,疗程 3mo。测定治疗前后 2组血糖、胰岛素、糖化血红蛋白及TNF和瘦素水平。结果 :治疗后 ,治疗组空腹和餐后 2h血糖下降 (1.0± 1.0 )和 (4±3)mmol·L- 1,TNF和瘦素下降 (0 .8± 0 .4 )和 (10±7) μg·L- 1,空腹和餐后 2h胰岛素下降 (3± 4 )和(8± 7)mU·L- 1,与治疗前及对照组相比 ,差异有显著或非常显著意义 (P <0 .0 5或P <0 .0 1)。结论 :罗格列酮可明显改善 2型糖尿病病人的血糖和胰岛素抵抗 。

AIM: To explore the effect of rosiglitzaone on tumor necrosis factor (TNF) and (leptin) in type 2 diabetic patients. METHODS: Forty-eight patients (M 24, F 24; age (58±s8)a) with type 2 diabetes were randomly divided into two groups. There were 24 patients in control or treatment group. All patients were treated with sulfonylurea and biguanide. Besides this, patients in treatment groups received rosiglitazone 4 mg·d^(-1) for 3 mo. The serum glucose, insulin, HbA_(1c), TNF and leptin level in both groups wre measured before and after treatment. RESULTS: After treatment, fasting and 2 h postprandial glucose decreased (1.0±1.0) and (4±3) mmol·L^(-1), fasting and 2 h postprandial insulin decreased (3±4) and (8±7) mU·L^(-1), TNF and leptin decreased (0.8±0.4) and ((10±)7) μg·L^(-1) in treatment group. There was significant difference compared with these before treatment and those of the control group(P<0.05 or P<(0.01)). CONCLUSION: Rosiglitazone can improve blood glucose and insulin resistance of type 2 diabetic patients. This may be related to the decreasing of TNF and leptin.